Third Quarter 2004 Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Epic growth proportions?: St. Jude Medical expects ICD sales of $570 mil.-$580 mil. in 2004. Reporting on the first full quarter with Epic HF and Atlas + HF CRT defibrillators on the market, the firm notes total ICD sales of $157 mil. in Q3, a 57% climb over the 2003 period. During the quarter, St. Jude extended its atrial fibrillation therapy portfolio, acquiring Irvine Medical and entering a purchase deal with Endocardial Solutions (1"The Gray Sheet" Sept. 27, 2004, p. 9). Earnings rose from $84 mil. in Q3 2003 to $91 mil. in Q3 2004, based on $578 mil. in sales, which represented 22% growth over last year. St. Jude took a special charge of $35 mil. for discontinuing Symmetry bypass aortic connectors...
You may also be interested in...
Medtronic ICD Growth Rate Hiccups On “Trialing” Of St. Jude Epic
Medtronic expects to quickly return to 20%-plus growth in its ICD business with the launch of its Insync Sentry cardiac resynchronization therapy defibrillator with thoracic fluid status monitoring
Medtronic ICD Growth Rate Hiccups On “Trialing” Of St. Jude Epic
Medtronic expects to quickly return to 20%-plus growth in its ICD business with the launch of its Insync Sentry cardiac resynchronization therapy defibrillator with thoracic fluid status monitoring
Pre-Holiday Savings: Device Firms Prepare For Repatriation Tax Bonanza
Johnson & Johnson intends to "repatriate" as much as $10 bil. held by foreign subsidiaries following President Bush's Oct. 22 signing of the "JOBS" bill into law